GlassScriptPhysician profile
Brett Kyle Billings
NPI 1174126346
$2,080.75
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.75 · 2022: $488 · 2023: $1,068 · 2024: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $434.51 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $318.85 | 2023-2024 | |
| Glaxosmithkline, LLC. | $179.21 | 2023-2024 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $135.93 | 2022 | |
| Pfizer INC. | $132.29 | 2023-2024 | |
| Exact Sciences Corporation | $121.03 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $112.20 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Organon LLC | $89.57 | 2022 | |
| Antares Pharma, INC. | $72.71 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Mylan Specialty L.P. | $55.59 | 2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $52.51 | 2022-2023 | |
| Halozyme INC | $42.00 | 2023 | |
| Daiichi Sankyo INC. | $41.11 | 2022 | |
| Coopersurgical, INC. | $39.89 | 2023 | Paragard T 380a |
| Astrazeneca Pharmaceuticals LP | $35.35 | 2024 | Airsupra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $35.18 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $31.52 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Acella Pharmaceuticals, LLC | $31.17 | 2022-2024 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.71 | 2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $24.41 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.41 | 2023 | |
| Tempus Ai, INC | $17.57 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.98 | 2023 | Trintellix |
| Nestle Healthcare Nutrition INC. | $14.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Billings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.